Yield of baseline imaging for distant metastases in high-risk primary melanoma.
PET computed tomography
diagnostic imaging
melanoma
staging
surveillance
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
16
02
2022
received:
18
12
2021
accepted:
22
02
2022
pubmed:
10
3
2022
medline:
17
5
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
The yield of baseline imaging in patients presenting with higher risk primary tumours, at least American Joint Committee on Cancer 8th edition stage IIC or III melanoma, is unclear. This retrospective study included patients referred to the Victorian Melanoma Service from January 2017 to April 2020, diagnosed with at least stage IIC or stage III melanoma. Patients with a T4b tumour and no sentinel lymph node biopsy were included as 'T4bNX'. One hundred and sixty-four patients (median age 65 years) with baseline imaging (T4bNX: 19, IIC: 30, IIIA: 21, IIIB: 43, IIIC: 50, IIID: 1) were included. The majority were male (73%), and those with T4bNX melanoma tended to be older (median age 79 years). Distant metastases were detected in 21% (4/19) of T4bNX, 3% (1/30) of stage IIC, 0% (0/21) of stage IIIA, and 6% (6/94) of stages IIIB-D melanoma patients. All stage III patients with distant metastases had palpable lymphadenopathy a presentation. Two patients had brain metastases, both of whom had T4bNX melanoma and synchronous extra-cranial metastases. Compared to stage IIC, baseline imaging detects higher rates of extra-cranial distant disease in stages IIIB-D and T4bNX melanoma. Intracranial imaging has greater yield in patients with distant extra-cranial disease.
Sections du résumé
BACKGROUND
BACKGROUND
The yield of baseline imaging in patients presenting with higher risk primary tumours, at least American Joint Committee on Cancer 8th edition stage IIC or III melanoma, is unclear.
METHODS
METHODS
This retrospective study included patients referred to the Victorian Melanoma Service from January 2017 to April 2020, diagnosed with at least stage IIC or stage III melanoma. Patients with a T4b tumour and no sentinel lymph node biopsy were included as 'T4bNX'.
RESULTS
RESULTS
One hundred and sixty-four patients (median age 65 years) with baseline imaging (T4bNX: 19, IIC: 30, IIIA: 21, IIIB: 43, IIIC: 50, IIID: 1) were included. The majority were male (73%), and those with T4bNX melanoma tended to be older (median age 79 years). Distant metastases were detected in 21% (4/19) of T4bNX, 3% (1/30) of stage IIC, 0% (0/21) of stage IIIA, and 6% (6/94) of stages IIIB-D melanoma patients. All stage III patients with distant metastases had palpable lymphadenopathy a presentation. Two patients had brain metastases, both of whom had T4bNX melanoma and synchronous extra-cranial metastases.
CONCLUSIONS
CONCLUSIONS
Compared to stage IIC, baseline imaging detects higher rates of extra-cranial distant disease in stages IIIB-D and T4bNX melanoma. Intracranial imaging has greater yield in patients with distant extra-cranial disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1312-1317Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784.
Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-1862.
Gyorki D, Teddy L, Barbour T, et al. Clinical question: When is a sentinel node biopsy indicated.? Clinical practice guidelines for the diagnosis and management of melanoma. Melanoma Institute Australia; 2018. https://wiki.cancer.org.au/australia/Guidelines:Melanoma
Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141(3):284-288.
Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110(5):1107-1114.
Morton R. Clinical question: what investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic stage I and II patients? In: Clinical practice guidelines for the diagnosis and management of melanoma. Melanoma Institute Australia, 2018. https://wiki.cancer.org.au/australia/Guidelines:Melanoma
National Institute for Health and Care Excellence. Melanoma: assessment and management, N.g. [NG14]. NICE 2021;2015.
Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-50.
Saw R, Menzies A, McArthur G, et al. Clinical question: what investigations should be performed when in transit and/or regional node disease (stage III melanoma) is diagnosed? In: Clinical practice guidelines for the diagnosis and management of melanoma. Melanoma Institute Australia, 2018. https://wiki.cancer.org.au/australia/Guidelines:Melanoma
Ravichandran S, Nath N, Jones DC, et al. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. Surg Oncol. 2020;35:533-539.
Arrangoiz R, Papavasiliou P, Stransky CA, et al. Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma. Dermatol Res Pract. 2012;2012:614349
Barsky M, Cherkassky L, Vezeridis M, Miner TJ. The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanoma. J Surg Oncol. 2014;109(7):726-729.
Wagner T, Chevreau C, Meyer N, Mourey L, Courbon F, Zerdoud S. Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol. 2012;26(11):1431-1435.
Hardie CM, Allouni A, Edwards S, Ahmed N, Maraveyas A, Matteucci PL. PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review. Melanoma Res. 2021;31(4):397-401.
Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006;24(18):2858-2865.
Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129-142.
Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23(1):11-16.
Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27(28):4774-4780.
Lewin J, Sayers L, Kee D, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018;29(7):1569-1574.
Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122(8):1770-1777.
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042-3047.